title: Effect of orally-administered Lactobacillus plantarum LPLM-O1 strain in an immunosuppressed mouse model of urinary tract infection.
abstract: Urinary tract infections (UTIs) affect both healthy and immunocompromised people, and they are treated with antibiotics. However, the high recurrence of UTIs obliges the use of natural mechanisms to regulate the normal microbiota through the use of e.g. lactic acid bacteria. In order to induce a UTI, 20 µl of the Escherichia coli (Ec-01) strain, in doses of 2.7×10(7) cfu/ml, was inoculated by way of the urethra in female Balb/c mice, all of them immunosuppressed with dexamethasone (10 mg/kg). Lactobacillus plantarum LPLM-O1 was used as a treatment, in daily doses of 1×10(7) cfu/ml, which were orally administered for seven days before the infection (preventive) or alongside the infection for seven days (curative). The oral administration of LPLM-O1 did not cause any adverse effects when used in an immunosuppressed animal model. It was observed that, when used as a preventive measure, LPLM-O1 induces a decrease in the infection, in the concentration of urinary leukocytes, and in the bacterial load. This study proposes the use of this lactic bacterium as a probiotic.
authors.affiliation: Universidad de Concepción, Facultad de Farmacia, Departamento de Bioquímica Clínica e Inmunología, Chile.
authors.forename: A Ramírez
authors.initials: AR
authors.lastname: de Arellano
authors.forename: M
authors.initials: M
authors.lastname: Sánchez
authors.forename: R
authors.initials: R
authors.lastname: Vera
authors.forename: S
authors.initials: S
authors.lastname: Jara
authors.forename: M
authors.initials: M
authors.lastname: González
authors.forename: E
authors.initials: E
authors.lastname: Castro
mesh_terms: D000284:Administration, Oral; D000818:Animals; D058491:Bacterial Load; D016207:Cytokines / Q000097:blood; D003907:Dexamethasone / Q000009:adverse effects; D004926:Escherichia coli / Q000472:pathogenicity; D004927:Escherichia coli Infections / Q000382:microbiology / Q000628:therapy*; D005260:Female; D016867:Immunocompromised Host; D007422:Intestines / Q000382:microbiology; D048191:Lactiplantibacillus plantarum / Q000254:growth & development* / Q000378:metabolism; D007962:Leukocytes / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D019936:Probiotics / Q000008:administration & dosage*; D014552:Urinary Tract Infections / Q000382:microbiology / Q000628:therapy*; D014556:Urine / Q000382:microbiology
chemical_list: D016207:Cytokines; D003907:Dexamethasone